A major study conducted in South Australia with almost 35000 participants has failed to show any discernible difference on herd immunity or throat carriage of Neisseria meningitidis

The study was led by vaccinologist Professor Helen Marshall, who was pleased the vaccine afforded a high level of protection among participants, with no cases of meningococcal disease occuring during the study, compared with 12 cases in the same age group in the two years prior. 

Alongside these findings, results of a UK study were published, estimating adjusted vaccine effectiveness to be 59% with a two-dose infant priming schedule plus a booster at 12 months of age since their publicly funded infant immunisation schedule began using the 4CMenB vaccine in 2015. 

Read the full article here:

AusDoc.Plus: No herd immunity: MenB vaccine ‘fails’ in school trial 

For further information about meningococcal vaccines, please refer to our Meningococcal disease and vaccines page

 

 

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。

分享这个